Golden Cross Formed, AstraZeneca Stock Drops 0.89% on Monday
On October 6, 2026: price 11,764.00 GBp, trend sideways, RSI 37.6, support 11,650.00, resistance 12,672.00. technical analysis of astrazeneca stock.

Correction, 6 October 2026: An earlier version of this analysis reported that AstraZeneca fell 2.23% and dated the price data to 2 October. The latest trading session was missing from the price feed, so the 5 October close was compared with the 1 October close and the indicators were calculated on data up to 2 October. The correct one-day move was a fall of 0.89%. Prices, indicators, charts and the data timestamp have been updated.
AstraZeneca fell 0.89% to 11,764.00 GBp at the close on 5 October, extending a five-day decline of 5.83%, according to market data from Yahoo Finance. The move leaves the London-listed shares below both their 20-day and 50-day averages, despite a recent golden cross—when the shorter-term average rises above the longer-term one. That crossover points to an improving underlying trend, but the latest price action shows it has not yet translated into near-term strength.Trend & Price Action
The shares are 3.5% below the 20-day simple moving average (SMA) of 12,190.30 GBp and 3.0% below the 50-day SMA of 12,132.52 GBp. The 20-day average has edged up by 0.10% over five days, while the broader trend is classified as sideways. Together, those readings suggest a weak pullback within an uncertain structure rather than a clear breakdown in the longer-term trend. The golden cross is a constructive signal, but price trading below both averages limits its confirmation. AstraZeneca is also close to the lower end of its recent range: the quoted position is 11% of the way from the 20-day support to resistance, while the three-month high and low stand at 14,526.00 GBp and 9,892.00 GBp. A range position near the bottom makes nearby support especially important. As shown in the chart, the lower Bollinger Band at 11,551.81 GBp is another reference point beneath the current price. Bollinger Bands track a moving average with boundaries based on price variation; the 10.5% band width is described as normal, not unusually compressed or expanded. The 17% %B reading places the price near the lower band, signalling pressure but not, by itself, a reversal.
Oscillators & Momentum
Momentum indicators are mixed, with the short-term readings weaker than the trend signal. The RSI is 37.6, a neutral reading; it is below the midpoint typically associated with stronger momentum, but not in the oversold zone. The Stochastic is oversold, with %K at 4.5 and %D at 14.5. This can occur after a sharp decline, but an oversold reading is not proof that selling has ended. The MACD is negative: its -28.547 reading is below the 31.643 signal line, with a -60.190 histogram. MACD compares shorter- and longer-term price averages to gauge momentum. Here, it reinforces the evidence of recent weakness and does not yet confirm a turn higher. The Stochastic’s oversold condition may leave room for a rebound, but confirmation would require improvement in price and momentum rather than the oscillator alone.
Volatility, Volume & Key Levels
The average true range (ATR), a measure of typical daily price movement, is 251.96 GBp, or 2.1% of the share price. That indicates moderate volatility: swings remain meaningful, but the data do not point to an exceptional expansion in daily movement. Trading volume was 1,619,066 shares, about half the 20-day average of 3,152,091, while on-balance volume (OBV)—a running measure that links volume with the direction of price changes—was declining. The low turnover means the sell-off was not accompanied by unusually heavy trading, but falling OBV offers little evidence that buyers are accumulating shares. The first nearby test is support at 11,650.00 GBp, just above the lower Bollinger Band. Holding that area could allow the shares to stabilise; a break below it would weaken the case for a short-term floor. On a recovery, the SMA20 at 12,190.30 GBp and SMA50 at 12,132.52 GBp are initial hurdles, followed by resistance at 12,672.00 GBp. A sustained move above that resistance would provide stronger evidence that the pullback has eased.Technical Verdict: HOLD (wait & see)
HOLD (wait & see) reflects the conflict between a golden cross and rising 20-day average on one side, and price below both averages, negative MACD momentum and declining OBV on the other. The oversold Stochastic could precede a bounce, but it has not yet been confirmed by the RSI or MACD. The verdict is invalidated if price breaks below 11,650.00 GBp, the stated 20-day support.- Ideal Entry Range: 11,551.81–11,650.00 GBp, using the lower Bollinger Band and support as reference levels.
- Exit Target: 12,672.00 GBp, the stated resistance level.
- Stop Loss: Below 11,551.81 GBp, the lower Bollinger Band.
Data
AZN.L, London Stock Exchange; market data, 5 October 2026, 22:39 WIB. Last price: 11,764.00 GBp; previous close: 11,870.00 GBp; daily change: -0.89%; five-day change: -5.83%; one-month change: -2.31%.
Summary Data AstraZeneca
| Last price | 11,764.00 GBp |
| Change 1 day / 5 days / 1 month | -0.89% / -5.83% / -2.31% |
| Trend / MA-cross | sideways / golden |
| SMA20 / SMA50 | 12,190.30 / 12,132.52 |
| RSI (14) / Stochastic %K | 37.6 / 4.5 |
| Bollinger %B / ATR | 17% / 251.96 |
| Support / Resistance 20 days | 11,650.00 / 12,672.00 |
| Data as of | 5 October 2026 22:39 WIB |
















